279. 巨大静脈奇形(頚部口腔咽頭びまん性病変) Huge venous malformation with cervical, oral and pharyngeal diffuse lesion Clinical trials / Disease details
臨床試験数 : 15 / 薬物数 : 24 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 105
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2009-011276-29-FR (EUCTR) | 21/08/2009 | 15/05/2009 | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | patients with congenital venous malformations (CVM) | Product Name: Ethanol gel Product Code: L0122 Other descriptive name: ETHANOL (96 PER CENT) Trade Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Product Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Other descriptive name: ETHANOL BP | ORFAGEN | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France | ||
2 | NCT00462462 (ClinicalTrials.gov) | May 2007 | 16/4/2007 | Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. | Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. | Congenital Venous Malformation | Drug: Ethanol 96% Gel;Drug: Ethanol 98% Solution | Orfagen | FDA Office of Orphan Products Development | Completed | 12 Years | N/A | All | 32 | Phase 2 | United States;France |